Racemethionine

Racemethionine

SCHEMBL287590

CSCCC(N)C(=O)O.CSCC[C@H](N)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BHMT Q93088 10/20 0.57
BHMT2 Q9H2M3 1/20 0.57
RNPEP Q9H4A4 1/20 0.56
NOS2 P35228 3/20 0.52
NOS3 P29474 2/20 0.52
NOS1 P29475 2/20 0.52
GRM8 O00222 1/20 0.50
GRM6 O15303 1/20 0.50
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
GSR P00390 1/20 0.50
CYP1A2 P05177 1/20 0.50
GRIK1 P39086 1/20 0.50
GRM5 P41594 1/20 0.50
GRIA1 P42261 1/20 0.50
GRIA2 P42262 1/20 0.50
GRIA3 P42263 1/20 0.50
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Racemethionine SCHEMBL16062299 1.00 BHMT (0.57) BHMTBHMT2RNPEPNOS2NOS3
Methionine SCHEMBL162030 1.00 BHMT (0.57) BHMTBHMT2RNPEPNOS2NOS3
Methionine SCHEMBL5584463 1.00 BHMT (0.57) BHMTBHMT2RNPEPNOS2NOS3
Racemethionine SCHEMBL9504290 1.00
Racemethionine SCHEMBL5617580 1.00 BHMT (0.57) BHMTBHMT2RNPEPNOS2NOS3
Racemethionine SCHEMBL8983115 1.00 BHMT (0.57) BHMTBHMT2RNPEPNOS2NOS3
Racemethionine SCHEMBL23361954 1.00 BHMT (0.57) BHMTBHMT2RNPEPNOS2NOS3
Methionine SCHEMBL4226 1.00
Racemethionine SCHEMBL126688 1.00
Racemethionine SCHEMBL31367634 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2449488-A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES BIOCRATES Life Sciences AG (AT) 2012-05-09 EP disclosed
EP-2427773-A1 METHOD OF DIAGNOSING ASPHYXIA Keller, Matthias (DE) 2012-03-14 EP disclosed
US-8034166-B2 Carbon dioxide absorbent requiring less regeneration energy BASF SE (DE) 2011-10-11 US disclosed
US-20110064828-A1 TREATMENT OF METASTATIC TUMORS AND OTHER CONDITIONS Novelos Therapeutics, Incorporated (US) 2011-03-17 US disclosed
WO-2011000753-A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES BIOCRATES LIFE SCIENCES AG (AT) 2011-01-06 WO disclosed
WO-2010128054-A1 METHOD OF DIAGNOSING ASPHYXIA BIOCRATES LIFE SCIENCES AG (AT) 2010-11-11 WO disclosed
US-20060270013-A1 Method for the production of evolved microorganisms which permit the generation or modification of metabolic pathways METABOLIC EXPLORER (FR) 2006-11-30 US disclosed
WO-2006042915-A1 FOODS AND METHODS FOR IMPROVING ANIMAL GROWTH ADISSEO IRELAND LIMITED (IE) 2006-04-27 WO disclosed
US-6777209-B1 DNA SEQUENCES ENCODING FOR RIBONUCLEOTIDE REDUCTASE AND THIOREDOXIN FURTHER COMPRISE DNA SEQUENCES ENCODING FOR THYMIDYLATE SYNTHASE AND/OR TRANSCRIPTION UNITS COMPRISING SEQUENCES ENCODING FOR URIDINE KINASE SMITHKLINE BEECHAM CORPORATION 2004-08-17 US disclosed
EP-1015479-A4 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR LILLY CO ELI (US) 2002-07-24 EP disclosed
EP-1015479-A1 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1998046631-A1 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR ELI LILLY AND COMPANY (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110064828-A1 TREATMENT OF METASTATIC TUMORS AND OTHER CONDITIONS PDIA5, GSTK1, GSTM2 BHMT 2933/4885BHMT2 3022/4885RNPEP 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.